DoW Tuberous Sclerosis Complex, Clinical Translational Research Award
About
Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Clinical Translational Research Award (CTRA) supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis or treatment of tuberous sclerosis complex (TSC). Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
The DoW Tuberous Sclerosis Complex Clinical Translational Research Award supports researchers committed to advancing the diagnosis, prognosis, and treatment of tuberous sclerosis complex (TSC). This grant program is designed for research teams ready to bridge the gap between promising laboratory discoveries and real-world clinical applications. If your research has demonstrated strong preclinical or early clinical findings and you're prepared to move that work toward practical clinical solutions, this award provides the funding and structure to make that advancement possible. The program uniquely supports collaborative research efforts by allowing multiple Principal Investigators to lead different components of a single project, with only the initiating PI required to submit a pre-application while partnering PIs submit abbreviated applications focused on their specific research contributions. This mechanism recognizes that complex translational research often requires multidisciplinary teams and distributed expertise. Researchers working on TSC diagnosis improvements, prognostic markers, or innovative treatment approaches should consider applying. The FY2026 funding cycle offers a meaningful opportunity to accelerate your translational research toward clinical impact.
Funding Facts
● Applications openDeadline
August 6, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by cycle - consult official program announcement
Deadline
2026-08-06
Grant Type
federal
Application Cycle
Annual - FY2026 deadline August 6, 2026
Best For
Research teams with multiple investigators studying tuberous sclerosis complex diagnosis, prognosis, and treatment
Frequently Asked Questions
Who is eligible for DoW Tuberous Sclerosis Complex, Clinical Translational Research Award?
Specific eligibility criteria are not detailed in the available program information. The award supports research teams with multiple Principal Investigators who have promising preclinical and/or clinical research findings ready for translational advancement. For complete eligibility requirements, including institutional type, researcher qualifications, and other specific criteria, visit the official Department of War (DoW) program website or contact the program office directly.
How much funding does DoW Tuberous Sclerosis Complex, Clinical Translational Research Award provide?
The specific funding amount or range for FY2026 is not specified in the available program information. Award amounts may vary based on project scope, research needs, and available appropriations. Check the official program announcement or contact the administering agency for current funding levels and budget guidelines for this cycle.
How do I apply for DoW Tuberous Sclerosis Complex, Clinical Translational Research Award?
The application process involves a two-stage submission for multi-PI projects: the initiating Principal Investigator submits a pre-application first, while all partnering PIs submit full applications along with the initiating PI. Partnering PIs provide abbreviated application packages specific to their research contributions. Note that if either the initiating or partnering application is rejected or administratively withdrawn, all associated applications for the project may be withdrawn. Consult the official program solicitation for detailed instructions, submission deadlines, and required documentation. The application deadline for FY2026 is August 6, 2026.
What can DoW Tuberous Sclerosis Complex, Clinical Translational Research Award funding be used for?
This award supports clinical translational research focused on moving promising research findings toward practical clinical application for tuberous sclerosis complex. Funded activities include research aimed at improving diagnosis of TSC, understanding disease prognosis, and developing new or improved treatments. The program specifically targets studies that bridge the gap between preclinical laboratory work and clinical implementation, with the goal of delivering real-world clinical benefits for TSC patients and clinicians.
Last updated: July 5, 2026